Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only some blood pressure, dizziness, hyperkalemia, kidney-related AEs, and angioedema claims are supported by the provided label excerpts. Multiple heart-rate-related claims (including HR not changing/being minor/not primary and mechanistic explanations) are not supported by the cited label content. Critical label areas (contraindications, boxed warnings, pregnancy, full drug interactions) were not evaluated in relation to the provided claims.
Category Scores
Accurate Statements
Entresto can cause low blood pressure, which may present with dizziness.
Supported by 5.3 (ENTRESTO lowers BP; may cause symptomatic hypotension) and 6.1/Table 3 (Dizziness 6% with ENTRESTO; Hypotension 18%).
Common side effects of Entresto include hyperkalemia.
Supported by 5.5 (Hyperkalemia may occur; monitor serum potassium) and 6.1/Table 3 (Hyperkalemia 12% with ENTRESTO).
Unsupported Statements
Entresto does not cause a large or consistent change in resting heart rate.
The provided label excerpts (12.2, 5.3, 5.2, 6.1) do not state anything about resting heart rate magnitude or consistency. The mention in 12.2 is about QT prolongation/no effect on cardiac repolarization, which does not support resting heart-rate change claims.
The main effects of Entresto include helping the heart work more efficiently in heart failure.
Not explicitly supported by the provided excerpts; 12.2 describes pharmacodynamic markers and BP effects rather than this exact 'more efficiently' framing.
Heart rate changes are not a primary effect of Entresto.
No provided label language establishes heart rate as an effect category or states it is not a primary effect.
Some people may notice no change in resting heart rate with Entresto.
No label excerpt provided supports individualized or population distribution statements about resting heart rate changes.
A small number of people might have a minor change in resting heart rate with Entresto.
No label excerpt provided quantifies 'small number' or provides evidence/AE table for resting heart rate changes.
The minor heart rate change observed in some people is often related to Entresto's blood pressure effects rather than a direct heart-rate action.
The provided excerpts do not state this causal interpretation regarding heart rate change mechanisms.
If a person is taking beta-blockers or other heart-rate-influencing drugs, the heart rate could be affected by those medications as well.
The provided excerpts do not support this interaction-specific heart-rate claim; section 7 (Drug Interactions) is listed but contains no provided text to substantiate the statement.
Contradictions
Low
AI Statement
Entresto does not cause a large or consistent change in resting heart rate.
Label Reference
Not supported by the provided label excerpts; no direct contradiction can be proven from the provided text, but the claim is unsubstantiated.
Important Omissions
Boxed warning/major safety statements were not assessed against any of the provided claims.
Importance:
High
Contraindications were not assessed (e.g., angioedema history/ACE inhibitor-related timing, hereditary angioedema, pregnancy-related contraindication/precautions).
Importance:
High
Drug interaction content was not available for evaluation (section 7 contains no provided text), so interaction-related claims (beta-blockers/heart-rate influence) cannot be verified.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsubstantiated heart-rate-related statements may mislead about physiologic effects. Additionally, critical label domains (boxed warnings/contraindications/pregnancy) were not evaluated, increasing risk of incomplete labeling alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple heart-rate-related claims are not supported by the provided label excerpts, and interaction-related heart-rate statements are not verifiable because section 7 text is not provided.
Suggested Improvement
Limit claims to what the provided label text explicitly supports (e.g., hypotension/dizziness, hyperkalemia, angioedema). Remove or rephrase heart-rate mechanistic and distribution claims unless the label excerpts explicitly address resting heart rate. Provide and evaluate complete label sections for contraindications, boxed warnings, pregnancy, and drug interactions (section 7) before asserting safety/interaction statements.